New Zealand - English - Ministry for Primary Industries

elanco new zealand - prednisolone; clavulanic acid present as potassium clavulanate; amoxicillin present as amoxicillin trihydrate - prednisolone 3.4 g/kg; clavulanic acid present as potassium clavulanate 16.67 g/kg; amoxicillin present as amoxicillin trihydrate 66.67 g/kg - anti-inflammatory

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - clavulanic acid present as potassium clavulanate; amoxicillin present as amoxicillin trihydrate - clavulanic acid present as potassium clavulanate 58.82 g/kg; amoxicillin present as amoxicillin trihydrate 235.2 g/kg - antibiotic

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin, quantity: 500 mg; clavulanic acid, quantity: 125 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; dimeticone 5000; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - augmentin tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology): urinary tract infections (uncomplicated and complicated); lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; skin and skin structure infections. appropriate culture and susceptibility studies should be performed to identify the causative organisms(s) and its (their) susceptibility to augmentin tablets. however, when there is reason to believe an infection may involve any of the b-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and b-lactamase producing organisms susceptible to augmentin tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - amoxicillin present as amoxicillin trihydrate; clavulanic acid present as potassium clavulanate - amoxicillin present as amoxicillin trihydrate 235.2 g/kg; clavulanic acid present as potassium clavulanate 58.82 g/kg - antibiotic

New Zealand - English - Ministry for Primary Industries

elanco new zealand - clavulanic acid present as potassium clavulanate; amoxicillin present as amoxicillin trihydrate - clavulanic acid present as potassium clavulanate 16.7 g/kg; amoxicillin present as amoxicillin trihydrate 66.7 g/kg - antibiotic

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin, quantity: 500 mg; clavulanic acid, quantity: 125 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - augmentin tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology): urinary tract infections (uncomplicated and complicated); lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; skin and skin structure infections. appropriate culture and susceptibility studies should be performed to identify the causative organisms(s) and its (their) susceptibility to augmentin tablets. however, when there is reason to believe an infection may involve any of the b-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and b-lactamase producing organisms susceptible to augmentin tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - clavulanic acid present as potassium clavulanate; prednisolone; amoxicillin present as amoxicillin trihydrate - clavulanic acid present as potassium clavulanate 16.67 g/kg; prednisolone 3.3 g/kg; amoxicillin present as amoxicillin trihydrate 66.67 g/kg - antibiotic

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - amoxicillin present as amoxicillin trihydrate; clavulanic acid present as potassium clavulanate - amoxicillin present as amoxicillin trihydrate 235.2 g/kg; clavulanic acid present as potassium clavulanate 58.82 g/kg - antibiotic

New Zealand - English - Ministry for Primary Industries

vetoquinol new zealand limited - amoxicillin present as amoxicillin trihydrate; clavulanic acid present as potassium clavulanate - amoxicillin present as amoxicillin trihydrate 400 g/kg; clavulanic acid present as potassium clavulanate 100 g/kg - antibiotic

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 1005 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; silicon dioxide; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam tablets should not require the addition of another antibiotic due to the amoxycillin content of curam tablets.